Compounds / KLOW Blend
KLOW Blend
Also known as: KLOW Stack; GHK-Cu + KPV + BPC-157 + TB-500 blend; KLOW 80mg (50/10/10/10); four-peptide repair and anti-inflammatory blend
Primary research focus: Tissue-repair, skin-remodeling, and anti-inflammatory research (combined GHK-Cu, KPV, BPC-157, and TB-500 blend)
Last updated July 2026 · Reviewed against FDA labeling and published research.
What is KLOW Blend?
The KLOW Blend is the GLOW formula with KPV added: GHK-Cu, BPC-157, and TB-500 plus the anti-inflammatory tripeptide KPV, in a single co-lyophilized vial. The standard presentation is an 80 mg vial split 50 mg GHK-Cu, 10 mg KPV, 10 mg BPC-157, and 10 mg TB-500. It is a vendor and community construct rather than a studied compound, it carries the same copper-related stability concerns as GLOW, and it compounds the general blend problem: with four components in a fixed ratio, attributing any effect (good or bad) to any one of them becomes impossible.
The blend has no mechanism of its own; it is four separate proposed mechanisms in one vial. GHK-Cu delivers copper and modulates extracellular-matrix and collagen gene programs. BPC-157 is studied for local angiogenesis via VEGFR2-Akt-eNOS signaling, with no identified receptor. TB-500 (Ac-LKKTETQ) binds G-actin and drives cell migration and angiogenesis. KPV, the C-terminal tripeptide of alpha-MSH, is taken up via the PepT1 transporter and directly inhibits NF-kB and MAP kinase inflammatory signaling, reducing TNF-alpha, IL-1beta, and IL-6, largely independent of melanocortin receptors. The stated rationale is that KPV addresses the inflammatory barrier to healing that the three-component GLOW formula leaves uncovered. That is a coherent hypothesis; it has not been tested. As with GLOW, the mass ratio is dominated by GHK-Cu (roughly 63 percent) because of its milligram-range dosing, not because of relative importance.
How it’s supplied
Not an FDA-approved or commercially manufactured medicine. It is sold by research-chemical vendors as a single co-lyophilized vial, standardly 80 mg total (50 mg GHK-Cu, 10 mg KPV, 10 mg BPC-157, 10 mg TB-500), though vial mass and split vary by supplier. It is also available as four separate vials, which is the safer path and preserves independent dosing.
Dosage Chart
Units shown are for a U-100 insulin syringe (100 units = 1 mL), calculated from the vial size and BAC water you select. For a blend, set the vial size to the total of all peptides in the vial; each dose is the combined amount, so one unit figure draws every component together in its fixed ratio. Always confirm against your prescription and your syringe markings.
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Weeks 1-2 | GHK-Cu: 1mgBPC-157: 200mcgKPV: 200mcgTB-500: 200mcg | 1x Daily | — |
| Weeks 3-4 | GHK-Cu: 2mgBPC-157: 400mcgKPV: 400mcgTB-500: 400mcg | 1x Daily | — |
| Weeks 5-8 | GHK-Cu: 3mgBPC-157: 600mcgKPV: 600mcgTB-500: 600mcg | 1x Daily | — |
- Rotate injection sites to reduce irritation and lipohypertrophy
- Not for use during pregnancy or breastfeeding
- Do not exceed the recommended dose to try to speed results
Potential Benefits and Side Effects
Effects reported in published research. Not a promise of results, and not medical advice.
- Reported for the individual components in preclinical research and, for GHK-Cu, small human topical studies; no benefit has been demonstrated for the blend, and direct human evidence for the combination does not exist.
- GHK-Cu: collagen, elastin, and glycosaminoglycan synthesis; wound healing and matrix remodeling.
- BPC-157: accelerated tendon, ligament, muscle, and bone healing in animal models; angiogenesis.
- TB-500: cell migration and angiogenesis via actin regulation in animal models.
- KPV: reduced intestinal and skin inflammation in animal models via direct NF-kB inhibition, without systemic immune suppression.
- Proposed four-pathway coverage adding anti-inflammatory control to the GLOW formula, which is the rationale for the combination.
- No human adverse-effect data exist for the blend; the following are component-level observations.
- Injection-site reactions, including redness.
- Mild drowsiness has been reported in community use, attributed to the GHK-Cu component.
- Copper-related effects with repeated dosing, including theoretical accumulation.
- KPV shows a clean preclinical profile with no pigmentation effects (unlike melanotan peptides), but no human tolerability data.
- A practical hazard specific to four-component blends: attribution and isolation of any adverse effect is impossible without stopping everything.
Warnings and contraindications
Important safety information. This is not exhaustive — read the full prescribing information and consult your prescriber or pharmacist.
- No FDA-approved labeling exists; the following reflect the blend's status and the limits of its evidence, not established label warnings.
- This is a blend, not a studied compound. No published clinical trial has evaluated this combination as a blend; whatever evidence exists belongs to the individual components studied separately, and combining them does not carry that evidence forward.
- The ratio is fixed by the seller, not derived from clinical data. Because all components share one vial, a single draw delivers all of them together and none can be titrated, paused, or dose-adjusted independently. If one component causes a problem, the only options are stopping everything or continuing everything.
- Pre-blending does not change the regulatory status of the individual components; each substance retains its own status, and the blend as a product is not on any FDA list.
- Co-lyophilized multi-peptide stability is not established. Compatibility, pH interactions, and per-component degradation rates in a shared vial are generally not characterized by the vendors selling these blends.
- A stability caveat specific to copper-containing blends: GHK-Cu is a copper(II) complex, and pre-mixing it with BPC-157 raises documented pH-compatibility concerns. Copper(II) is also a redox-active metal capable of catalyzing oxidative degradation of other peptides in solution. Per-component degradation rates in a shared copper-containing vial are not characterized by the vendors selling these blends. Sourcing the components as separate vials avoids this entirely and preserves independent dosing.
- With four components in a fixed ratio, attribution becomes impossible: if the blend helps, there is no way to know which component was responsible; if it causes an adverse effect, there is no way to isolate the cause without stopping everything.
- Component status is unresolved and differs per substance: BPC-157, TB-500, and KPV were removed from Category 2 in April 2026 but not added to the 503A bulks list, and all three went before the Pharmacy Compounding Advisory Committee on July 23, 2026 (with the FDA proposing that TB-500 not be added); injectable GHK-Cu is scheduled for a separate later meeting due before the end of February 2027.
- TB-500 is prohibited at all times in sport under WADA Section S0; BPC-157 has also appeared on the WADA list. This blend is not usable by tested athletes.
- Copper accumulation from GHK-Cu is a real consideration with repeated dosing and is the main reason community protocols cycle off; caution applies in copper-metabolism disorders such as Wilson disease.
- None of the four components has completed a human efficacy trial for these uses; KPV in particular has no completed human clinical trials at all.
- Safety in pregnancy and breastfeeding has not been studied.
- Not established; no FDA-approved labeling. Precautionary considerations carry over from the components: active or suspected malignancy (given proposed angiogenic and cell-migration effects), disorders of copper metabolism such as Wilson disease, known hypersensitivity to copper or to any component peptide, and use by athletes subject to anti-doping rules.
Reconstitution Steps
How to prepare the lyophilized vial. Confirm specifics with your pharmacist or prescriber.
- This is a multi-component blend supplied as a single co-lyophilized vial, so all components share one diluent volume and are drawn together in a fixed ratio. Confirm the total vial mass AND the per-component split before starting; the ratio cannot be adjusted after reconstitution.
- For this blend specifically: the standard vial is 80 mg total, split 50 mg GHK-Cu, 10 mg KPV, 10 mg BPC-157, and 10 mg TB-500. Vial mass and split vary by supplier, so confirm yours before calculating; four separate concentration calculations are required.
- Expect a blue or blue-green tint after reconstitution from the copper component; that is normal for GHK-Cu, though a color change over time may indicate degradation.
- Wash your hands and gather supplies: the blend vial, the diluent (typically bacteriostatic water), an alcohol swab, and a sterile syringe.
- Let the vial and diluent reach room temperature if they were refrigerated or frozen.
- Wipe the rubber stopper of both the blend vial and the diluent vial with a fresh alcohol swab and let them air dry.
- Draw the intended diluent volume into the syringe.
- Insert the needle into the vial and slowly release the diluent down the inside wall rather than directly onto the powder, to avoid foaming.
- Do not shake. Gently swirl or roll the vial until fully dissolved.
- Inspect the solution: it should be clear with no visible particles. Do not use if cloudy or containing particles.
- Calculate concentration per component, not just for the blend: divide EACH component's mass by the same diluent volume. The calculator on this page computes a single concentration, so run it once per component using that component's mass.
- Label the vial with the reconstitution date and the full per-component concentration breakdown, and store as directed under reconstituted storage.
US regulatory status
Classifications are public record but can change. For reference only, not legal advice.
Development: KLOW has no development history of its own: it is a vendor and community extension of the GLOW formula, and no published clinical trial has evaluated the four-peptide combination together. The component histories are separate and unequal. GHK-Cu has the largest research base (mostly in vitro and animal, plus small human topical studies). BPC-157 has an extensive preclinical literature with human evidence limited to a few small uncontrolled pilots. TB-500 has animal wound-healing data but no completed published human efficacy trial. KPV has a well-characterized two-decade preclinical base, anchored by Dalmasso and colleagues (Gastroenterology, 2008) showing PepT1-mediated uptake and NF-kB inhibition reducing experimental colitis, and Kannengiesser and colleagues (2008) in murine IBD models, but no completed human clinical trials. Regulatory paths have diverged: BPC-157, TB-500, and KPV all went before the Pharmacy Compounding Advisory Committee on July 23, 2026, while injectable GHK-Cu was deferred to a later meeting due before the end of February 2027.
Notes: KLOW is not FDA-approved, and blends as such are not on any FDA list; compounding eligibility is determined per substance, and pre-blending does not change any component's status. The four components are on two tracks: BPC-157, KPV, and TB-500 were removed from FDA Category 2 on April 15, 2026 but not added to the 503A bulks list, and all three went before the Pharmacy Compounding Advisory Committee on July 23, 2026 (with the FDA proposing that TB-500 not be added, citing inadequate evidence and characterization); injectable GHK-Cu was also removed from Category 2 but is scheduled for a later meeting due before the end of February 2027. Because eligibility is per substance, this blend has a lawful compounding path only if all four components do, which makes it the most exposed of the common blends to an adverse determination on any single component. Verify each against the current FDA list. TB-500 is prohibited in sport under WADA Section S0. None of the components is a controlled substance. (Status current as of mid-2026.)
International status
Pharmacokinetics
Storage and handling
Important Notes
Practical considerations for consistency and safety.
- No published trial has evaluated these four peptides together; direct human evidence for the KLOW combination does not exist.
- KLOW is the most exposed of the common blends to regulatory risk: it needs all four components to clear, and they sit on two different advisory committee tracks (BPC-157, KPV, and TB-500 on July 23, 2026; injectable GHK-Cu at a later meeting before end of February 2027).
- Copper chemistry is a genuine objection to the single-vial format: pre-mixing GHK-Cu with BPC-157 raises pH-stability concerns, and copper(II) can catalyze oxidative degradation of the other peptides.
- With four components in a fixed ratio, no effect can be attributed to any one of them, and no component can be paused independently.
- KPV is the component with the least human data: two decades of solid preclinical work, zero completed human trials.
- Copper accumulation is the main driver of the cycling-off convention.
Lifestyle Factors
- Community protocols typically cycle (commonly 4 to 6 weeks on, 2 to 4 weeks off), with copper accumulation from the GHK-Cu component cited as the main driver of the off period.
- Human lifestyle interactions are not characterized for any component in this context.
References
Related compounds
Important disclaimer
This page is an educational reference, not medical advice, a diagnosis, or a treatment recommendation, and not a substitute for your prescriber or pharmacist. Approval and regulatory status varies by compound and can change. Always confirm against current prescribing information and consult a qualified healthcare professional before making any decision about a medication.